France Approves Reimbursement for Anti-Obesity Drug Wegovy
The decision allows patients with severe obesity to access the costly treatment through public health coverage, following evidence of cardiovascular benefits.
- The Haute Autorité de Santé (HAS) has approved the reimbursement of Wegovy for adults with a Body Mass Index (BMI) of 35 kg/m² or higher, classified as severe obesity.
- The approval follows new data showing Wegovy's effectiveness in reducing cardiovascular risks and achieving an average weight loss of 17%.
- The treatment, a weekly injectable medication, must be paired with a low-calorie diet and increased physical activity for weight management.
- Previously restricted to adults under 65, the HAS has now lifted the age limit for reimbursement eligibility.
- Wegovy's high cost, previously only accessible to self-financing patients, will now be covered for an estimated 1 to 2.1 million eligible individuals in France.
L'Express 
Sud Ouest 